Centessa Pharmaceuticals (CNTA) Income towards Parent Company: 2022-2025
Historic Income towards Parent Company for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$54.9 million.
- Centessa Pharmaceuticals' Income towards Parent Company fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
- Centessa Pharmaceuticals' Income towards Parent Company amounted to -$54.9 million in Q3 2025, which was down 9.03% from -$50.3 million recorded in Q2 2025.
- In the past 5 years, Centessa Pharmaceuticals' Income towards Parent Company registered a high of -$24.9 million during Q2 2023, and its lowest value of -$111.3 million during Q4 2024.
- Its 3-year average for Income towards Parent Company is -$47.1 million, with a median of -$42.6 million in 2024.
- As far as peak fluctuations go, Centessa Pharmaceuticals' Income towards Parent Company skyrocketed by 61.51% in 2023, and later crashed by 202.22% in 2024.
- Centessa Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$43.2 million in 2022, then increased by 14.68% to -$36.8 million in 2023, then crashed by 202.22% to -$111.3 million in 2024, then declined by 28.96% to -$54.9 million in 2025.
- Its Income towards Parent Company was -$54.9 million in Q3 2025, compared to -$50.3 million in Q2 2025 and -$26.1 million in Q1 2025.